Neoadjuvant Therapy and Factors Influencing Survival in Locally Advanced Non-Small Cell Lung Cancer

Basit Öğe Kaydı
dc.contributor.authorEbinc, Senar
dc.contributor.authorOruc, Zeynep
dc.contributor.authorKalkan, Ziya
dc.contributor.authorTeke, Fatma
dc.contributor.authorOnat, Serdar
dc.contributor.authorUrakci, Zuhat
dc.contributor.authorKaplan, Muhammet Ali
dc.date.accessioned2024-04-24T17:33:07Z
dc.date.available2024-04-24T17:33:07Z
dc.date.issued2023
dc.departmentDicle Üniversitesien_US
dc.description.abstractAim: We aimed to investigate the effectiveness of neoadjuvant therapy (NAT) and clinicopathological characteristics in locally advanced non-small cell lung cancer (NSCLC) (IIIA-IIIB), as well as the influence of the post-NAT treatment modalities on survival. Materials and methods: This study included patients who presented to the Dicle University Medical Oncology Clinic and received NAT for a diagnosis of locally advanced NSCLC between 2004 and 2020. Clinicopathological and radiological data of the 57 patients whose data could be retrieved from the hospital archive system were retrospectively reviewed. Patients' overall survival (OS) and failure-free survival (FFS) times and the factors influencing these times were evaluated. Results: This study included a total of 57 patients consisting of five (8.8%) females and 52 (91.2%) males. The median patient age at diagnosis was 58 (30-75) years. All patients had received four courses of chemotherapy during the neoadjuvant period. When the factors influencing OS were evaluated, the post-NAT modality was found to have a statistically significant effect on survival. FFS times were 12, 13, and 16 months in the chemotherapy, chemoradiotherapy, and surgery arms, respectively (log-rank p=0.035). FFS was longer in those who underwent surgery (Hazard ratio (HR): 0.33, 95 % CI: 0.14-0.77, (p=0.01)). OS times were 20, 21, and 55 months in the chemotherapy, chemoradiotherapy, and surgery arms, respectively (log-rank p=0.05). OS was longer in the arm undergoing surgery compared to the other arms (HR: 0.36, 95% CI: 0.14-0.87, (p=0.02)). Five-year survival rates for the chemotherapy, chemoradiotherapy, and surgery arms were 14.3%, 21.4%, and 40%, respectively. Conclusions: This study shows that achieving an operable status is the most important indicator of survival and that patients undergoing surgery have a marked advantage in OS and FFS compared with patients receiving chemoradiotherapy or palliative chemotherapy.en_US
dc.identifier.doi10.7759/cureus.33392
dc.identifier.issn2168-8184
dc.identifier.issue1en_US
dc.identifier.pmid36751212en_US
dc.identifier.urihttps://doi.org/10.7759/cureus.33392
dc.identifier.urihttps://hdl.handle.net/11468/20438
dc.identifier.volume15en_US
dc.identifier.wosWOS:000921559400015en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSpringernatureen_US
dc.relation.ispartofCureus Journal of Medical Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectMultimodal Treatmenten_US
dc.subjectSurgeryen_US
dc.subjectChemoradiotherapyen_US
dc.subjectLung Canceren_US
dc.subjectNeoadjuvant Chemotherapyen_US
dc.titleNeoadjuvant Therapy and Factors Influencing Survival in Locally Advanced Non-Small Cell Lung Canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu